Hepatitis A: Difference between revisions

 
(7 intermediate revisions by 4 users not shown)
Line 1: Line 1:
==Background==
==Background==
 
*Transmission by
==Clinical Features==
*Transmission
**Fecal-oral route
**Fecal-oral route
**Most commonly transmitted from asymptomatic children to adults
**Most commonly transmitted from asymptomatic children to adults
**Can also occur with improper food handling, oyster consumption
**Can also occur with improper food handling, oyster consumption
*Clinical course
 
**Incubation period 15-50 days
==Clinical Features==
**Prodrome of nausea, vomiting, malaise
[[File:Jaundice eye.jpg|thumb|Jaundice from Hepatitis A.]]
**~1wk into illness, may have dark urine (bilirubinuria), clay-colored stools, jaundice
*Incubation period 15-50 days
*Prodrome of [[nausea/vomiting]], malaise
**~1 week into illness, may have dark urine (bilirubinuria), clay-colored stools, [[jaundice]]
*No chronic component
*No chronic component
*~1-2% of HAV infections in adults lead to fulminant hepatic failure
*Can cause aversion to tobacco among smokers
*Death from hepatic failure is rare
*~1-2% of HAV infections in adults lead to fulminant [[hepatic failure]]
*Death from [[hepatic failure]] is rare


==Differential Diagnosis==
==Differential Diagnosis==
Line 18: Line 19:


==Evaluation==
==Evaluation==
[[File:Hepatitis A serology.jpg|thumb|Hepatitis A serology.]]
{{Acute hepatitis panel}}
{{Acute hepatitis panel}}


==Management==
==Management==
*Supportive care
*Supportive care
**antiemetics
**[[Antiemetics]]
**oral or IV hydration
**[[oral rehydration therapy|Oral]] or [[IVF|IV hydration]]
**avoid hepatotoxic medications
**Avoid hepatotoxic medications
*Patients with fulminant hepatic failure (1-2% of HAV infections) may be considered for liver transplant
*Patients with fulminant hepatic failure (1-2% of HAV infections) may be considered for liver transplant
*Postexposure prophylaxis recommend for non-immunized close contacts of patient
*Postexposure prophylaxis recommend for non-immunized close contacts of patient


==Disposition==
==Disposition==
*Typically discharge, admit if:
**INR >2
**Unable to tolerate PO
**Intractable pain
**Bilirubin >30
**[[Hypoglycemia]]
**Significant comorbidity/immunocompromised


==See Also==
==See Also==

Latest revision as of 20:34, 28 February 2024

Background

  • Transmission by
    • Fecal-oral route
    • Most commonly transmitted from asymptomatic children to adults
    • Can also occur with improper food handling, oyster consumption

Clinical Features

Jaundice from Hepatitis A.
  • Incubation period 15-50 days
  • Prodrome of nausea/vomiting, malaise
    • ~1 week into illness, may have dark urine (bilirubinuria), clay-colored stools, jaundice
  • No chronic component
  • Can cause aversion to tobacco among smokers
  • ~1-2% of HAV infections in adults lead to fulminant hepatic failure
  • Death from hepatic failure is rare

Differential Diagnosis

Causes of acute hepatitis

Evaluation

Hepatitis A serology.

Interpreting Acute Hepatitis Panel Results

Anti-hepatitis A, IgM Hepatitis B surface antigen Anti-hepatitis B core, IgM Anti-hepatitis C Interpretation
Positive Negative Negative Negative Acute hepatitis A
Negative Positive Positive Negative Acute hepatitis B
Negative Positive Negative Negative Chronic hepatitis B infection
Negative Negative Positive Negative Acute hepatitis B; quantity of hepatitis B surface antigen is too low to detect
Negative Negative Negative Positive Acute or chronic hepatitis C; additional tests are required to make the determination

Management

  • Supportive care
  • Patients with fulminant hepatic failure (1-2% of HAV infections) may be considered for liver transplant
  • Postexposure prophylaxis recommend for non-immunized close contacts of patient

Disposition

  • Typically discharge, admit if:
    • INR >2
    • Unable to tolerate PO
    • Intractable pain
    • Bilirubin >30
    • Hypoglycemia
    • Significant comorbidity/immunocompromised

See Also

External Links

References

  1. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 Dec 17; 137(12): 947-54.